Navigation Links
Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Date:12/7/2009

r response (CR, PR or MR), was the primary endpoint, with Time to Progression (TTP), Progression-Free Survival (PFS), Overall Survival (OS) and Safety as secondary endpoints.

Seventy-three patients were evaluable for efficacy. Evaluable patients are defined as those patients who had received at least two cycles of therapy on the combination of perifosine with bortezomib. Of the 73 evaluable patients, 53 patients (73%) were previously refractory to bortezomib (defined as progression on or within 60 days of treatment to a bortezomib-based regimen), including 44 patients who were refractory to the combination of bortezomib + dexamethasone. Twenty evaluable patients (27%) were relapsed to a prior bortezomib-based regimen. Best response for all 73 evaluable patients was as follows:




   Evaluable
    Patients    CR /nCR*      PR        MR         ORR        SD**
   ---------    --------   --------   -------    -------    -------
 All Evaluable
    Patients
     (n=73)      3    4%   13   18%   14  19%    30  41%    30  41%
 -------------  ---  ---   ---  ---   --- ---    --- ---    --- ---
   Bortezomib
    Relapsed
     (n=20)      2   10%    7   35%    4  20%    13  65%     7  35%
   ----------   ---  ---   ---  ---   --- ---    --- ---    --- ---
   Bortezomib
   Refractory
     (n=53)      1    2%    6   11%   10  19%    17  32%    23  43%
   ----------   ---  ---   ---  ---   --- ---    --- ---    --- ---

*   nCR = Near Complete Response is defined as meeting the criteria
    for CR (non-detectable monoclonal protein by serum and urine),
    except with detectable monoclonal protein by immunofixation.
**  SD = Stable Disease for a minimum of 3 months.

Approximately 60% (45 / 73) of patients demonstrated progression (or SD for 4 cycles) at some point in their treatment and received 20 mg dexamethasone, four times per week, in addition to perifosine plus bortezomib. Responses occurred both with patients taking perifosine in co
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... PRUSSIA, Pa. , May 22, 2015  The ... its 2015 Corporate Leadership Award as recognition for the ... the care of the bleeding disorders community.  The award was ... CSL Limited, during the NHF Annual Spring Soiree in ... "The National Hemophilia Foundation is dedicated to finding better ...
(Date:5/22/2015)... 2015   InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" ... ("EPS"), today announced that its CGuard TM Embolic Prevention ... Prof. Piotr Musialek , at the EuroPCR ... . PARADIGM, an investigator-initiated P rospective ... roti D revascularization I n symptomatic and increased-risk ...
(Date:5/22/2015)... , May 22, 2015 AcelRx Pharmaceuticals, ... focused on the development and commercialization of innovative therapies ... announced that interim chief executive officer Howie Rosen ... and chief financial officer Tim Morris will ... of the two presentations are as follows: ...
Breaking Medicine Technology:National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2
(Date:5/22/2015)... Lehi, Utah (PRWEB) May 22, 2015 Mountain ... will host a ribbon cutting ceremony on Friday, May 29, ... 1 p.m. to 6 p.m. The new medical center, set ... 3000 North Triumph Boulevard, Lehi, UT 84043. , “The ... for our team and the Utah County community,” said Kent ...
(Date:5/22/2015)... May 22, 2015 Following yesterday’s announcement ... agreement with US-based health brand Nature’s Way, Marc St-Onge ... Retention of Ascenta Skin is an integral part of ... about this opportunity to further develop Ascenta Skin into ... Ascenta Skin is a breakthrough, anti-aging skincare supplement featuring ...
(Date:5/22/2015)... Hands On HealthCare Massage Therapy and ... Annual One Day Sale on Massage and Facial ... offers drastically reduced certificates one day a year. This sale ... through what used to be the slowest time of the ... as well. This once a year occurrence has become a ...
(Date:5/22/2015)... Carnegie Science Center and Allegheny ... to develop BodyTech, a dynamic, three-pronged health and science ... new exhibit at the Science Center called BodyWorks, the ... traveling science show, Anatomy Adventure, which will hit the ... to explore a wide range of topics surrounding health ...
(Date:5/22/2015)... According to a new Aegis Living Study on Attitudes ... to worry about what will happen to their memory as ... Silent Generation), which may help explain why nearly half of ... Millennials (47%), Gen X’ers (51%), and Boomers (43%). The study ... more than 2,000 U.S. adults ages 18+. , “This ...
Breaking Medicine News(10 mins):Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:New Study Reveals America’s Fear of Aging 2Health News:New Study Reveals America’s Fear of Aging 3
... as a key resource for finding the best Government and nonprofit ... straightforward and credible information catalogued on the site. But it is ... for disease prevention and wellness information interactive and action oriented. ... ...
... Amoena, the worldwide leader of post-breast surgery ... Hannah Collection, the industry,s first post-surgical garments ... ease discomfort after breast surgery.(Logo: ... http://www.newscom.com/cgi-bin/prnh/20090408/CL96087 )The post-surgical camisole ...
... ORTHOCON¿ Inc. today announced that Paul R. Sohmer, ... Executive Officer. The company also announced the closing of ... healthcare investors. ORTHOCON is developing innovative implantable devices ... platform may be leveraged to deliver a variety of ...
... high marks on intentions for good nutrition but lack ... no surprise that with the current economic conditions, three-quarters ... healthy eating is largely dependent on what food families ... family pantries, fridges, and freezers, Rutgers University ...
... 8 Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) ... BG Medicine (BGM) in its Phase 2 clinical safety ... this collaboration, BGM will measure levels of Galectin-3 in ... for cardiac remodeling associated with advanced stages of heart ...
... April 8 The College of American Pathologists (CAP), ... and deeming authority under the Clinical Laboratory Improvement Amendments ... Services (CMS) since 1995, has been notified that it ... a six-year period, the longest period available for this ...
Cached Medicine News:Health News:healthfinder.gov Adds New Interactive Features to Its Web Site 2Health News:Amoena Introduces First Post Surgical Garments With Vitamin E & Aloe to Help Soothe and Comfort After Breast Surgery 2Health News:ORTHOCON Announces Appointment of New CEO and $25 Million Series B Financing 2Health News:Rutgers Study Reveals A Need For Basic Kitchen Know-How 2Health News:Rutgers Study Reveals A Need For Basic Kitchen Know-How 3Health News:Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers 2Health News:Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers 3Health News:Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers 4Health News:CAP Deeming Status Renewed 2
... of the spine. Comfortable support ... provided for all body types ... in both superior and inferior ... be positioned for a wide ...
Adjust-A-Tip cautery....
6 mm, 45 degree upwards, detachable....
Sabre 180 is a powerful niche generator....
Medicine Products: